# A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation

> **NCT06682806** · PHASE2 · TERMINATED · sponsor: **Prelude Therapeutics** · enrollment: 6 (actual)

## Conditions studied

- Advanced Solid Tumor
- Esophageal Cancer
- Metastatic Solid Tumor
- Non-small Cell Lung Cancers
- SMARCA4 Gene Mutation

## Interventions

- **DRUG:** PRT3789
- **DRUG:** pembrolizumab

## Key facts

- **NCT ID:** NCT06682806
- **Lead sponsor:** Prelude Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2025-06-03
- **Primary completion:** 2026-01-23
- **Final completion:** 2026-01-23
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2026-02-02

## Collaborators

- Merck Sharp & Dohme LLC

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06682806

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06682806, "A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation". Retrieved via AI Analytics 2026-08-21 from https://api.ai-analytics.org/clinical/NCT06682806. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*